Proqr Therapeutics PRQR

$1.57 -0.06 (-3.68%)

Valuation

Market cap
173,849,000
Revenue TTM
$18,000,000
Net income TTM
$-47,730,000
PE ratio
0.00
Forward PE
—
Profit margin
-265.17%
Debt to equity
0.06

Trading

Volume
1,163,141
Avg volume
783,314
Day's range
$1.54 – $1.62
Shares out
105,363,000
Stochastic %K
47%
Beta
0.20
Analysts
Strong Sell
Price target
$7.78

Price

Company profile

ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also...

Show more

ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Industry
Biotechnology
Sector
Healthcare
Phone
31 88 166 7000
Website
https://www.proqr.com
Address
Zernikedreef 9, Leiden, Netherlands

Latest news

Stocktwits

JCLuckman Oct 8, 8:07 PM
$PRQR picking up a few more.. TY
0 replies
Filvul Oct 8, 3:37 PM
$PRQR why is this falling so hard?
1 replies
johnnygogogo Oct 8, 3:15 PM
$PRQR below every recent insider buy. 50% below LLY avg price per share not including upfront or milestones. You should all sell your positions now while the fake funds blow up. @skeezbag
3 replies
LoveRetailFroth Oct 8, 2:14 PM
$TSHA Good Morning ☕️ Ridiculous price🤦‍♂️ on all 4. $PRQR $PRME $TELO
1 replies
Akex1987ita Oct 8, 9:19 AM
$PRQR A new AASLD 2026 abstract on AX-0810 has appeared in the LARVOL database, covering safety, pharmacokinetics and NTCP target engagement. This is the first specific conference reference identified, but inclusion of the 9 mg/kg cohort and 12-week follow-up data remains unconfirmed. No new clinical results have been verified yet.
1 replies
LoveRetailFroth Oct 6, 1:17 PM
$PRME Good Morning ☕️ Loaded up 50k over the last 3 weeks. Let’s go $5 starters. Watch $PRQR with boatload of money! $TELO $TSHA
1 replies
Filvul Oct 5, 8:24 PM
$PRQR catalysts are coming!!!
1 replies
LoveRetailFroth Oct 5, 5:26 PM
$RXRX 2027 other bios .. $PRME $PRQR $TSHA
0 replies